preliminary results of allogenic hematopoietic stem cell transplantation of non-m3 acute myeloid leukemia

Authors

farhad shahi department of hematology and medical oncology, cancer research center, cancer institute, imam khomeini hospital complex, tehran university of medical sciences, tehran, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (tehran university of medical sciences)

marziye ghalamkari internal medicine resident, imam khomeini hospital complex, tehran university of medical sciences, tehran, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (tehran university of medical sciences)

seyed reza safayi department of hematology and medical oncology, cancer research center, cancer institute, imam khomeini hospital complex, tehran university of medical sciences, tehran, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (tehran university of medical sciences)

mehrzad mirzania department of hematology and medical oncology, cancer research center, cancer institute, imam khomeini hospital complex, tehran university of medical sciences, tehran, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (tehran university of medical sciences)

abstract

background: allogeneic hematopoietic stem cell transplantation (allo-hsct) is used as treatment of choice for patients with acute myeloid leukemia (aml). we aimed to evaluate the prognostic factors in 2-year overall survival of patients with non-m3 aml who underwent allogenic hsct. methods: this is a cross sectional retrospective study. demographic data and study of variables such as age, sex, complete remission status, karnofsky performance status scale at baseline and at time of transplantation, occurrence of gvhd (acute and chronic), relapse and 2-year survival were extracted from records of 49 patients who underwent allogenic hsct from years 2006-2013 at bmt center in imam khomeini hospital. all autologous scts and m3 cases were not included. all data were analyzed with spss software. p< 0.05 was considered as statistically significant. results: the overall survival rate was 55% in the patients. there was no significant difference in overall survival between complete remission (cr) 1 and cr2. relapse rate was 6%. mean 2-year karnofsky scale was 93.7. mean admission time following bmt was 22 days which was significantly related to 2-year performance status (p=0.02). admission complication rate was 22.5% (gvhd 12%). rate of overall gvhd was 55%, 40% of whom developed chronic gvhd which had a positive effect on 2-year overall survival (os2).the patient's first performance state (k1) had a significant correlation with 2-year performance state (p< 0.05) and os2 (p< 0.05). conclusion: chronic gvhd and initial karnofsky performance status scale can be considered as good prognostic factors in patients with aml who undergo allo-hsct.

Upgrade to premium to download articles

Already have an account?login

similar resources

Preliminary Results of Allogenic Hematopoietic Stem Cell Transplantation of non-M3 Acute Myeloid Leukemia

Background:  Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) is used as treatment of choice for patients with acute myeloid leukemia (AML). We aimed to evaluate the prognostic factors in 2-year overall survival of patients with non-M3 AML who underwent allogenic HSCT. Methods: This is a Cross sectional retrospective study. Demographic data and study of variables such as age...

full text

150 Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

 Poorto intermediate-risk acute myeloid leukemia (AML) in remission  AML that is refractory to standard induction chemotherapy but can be brought into CR with intensified induction chemotherapy  AML that relapses following chemotherapy-induced CR1 but can be brought into CR2 or beyond with intensified induction chemotherapy; or  AML in patients, who have relapsed following a prior autologou...

full text

Hematopoietic stem cell transplantation for acute myeloid leukemia.

Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) yields a high rate of curability for acute myeloid leukemia (AML), it is also associated with transplant-related morbidity and mortality (TRM). The risk and severity of TRM increase with the use of an alternative donor graft in the absence of an HLA-matched sibling donor (MSD). With the declining birthrate and aging of the ...

full text

Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia - 9/15

Acute myeloid leukemia (AML) refers to a set of leukemias that arise from a myeloid precursor in the bone marrow. There is a high incidence of relapse, which has prompted research into a variety of postremission strategies using either allogeneic or autologous hematopoietic stem cell transplantation (HSCT). HSCT refers to a procedure in which hematopoietic stem cells are infused to restore bone...

full text

Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia

Acute myeloid leukemia (AML) (also called acute nonlymphocytic leukemia) refers to a set of leukemias that arise from a myeloid precursor in the bone marrow. There is a high incidence of relapse, which has prompted research into a variety of post-remission strategies using either allogeneic or autologous hematopoietic stem-cell transplantation (HSCT). HSCT refers to a procedure in which hematop...

full text

Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}

Journal title:

iranian journal of blood and cancer

جلد ۸، شماره ۲، صفحات ۵۲-۵۵

Keywords

[ ' p r o g n o s t i c f a c t o r s ' , ' k a r n o f s k y p e r f o r m a n c e s t a t u s s c a l e ' , ' g v h d ' , 2 , ' y e a r o v e r a l l s u r v i v a l ' , ' n o n ' , ' m 3 a m l ' , ' a l l o g e n i c s t e m c e l l t r a n s p l a n t a t i o n ' , ' a u t o l o g o u s s t e m c e l l t r a n s p l a n t a t i o n ' ]

Hosted on Doprax cloud platform doprax.com